Hi. Good afternoon, everybody. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID Biotech Analysts at UBS. Happy to introduce Spyre Therapeutics. We have with us Cameron Turtle, CEO. Thank you so much for joining us, Cameron. Good to see you.
Appreciate for having us.
So maybe just to level set for the audience, for people who might not be as familiar with the story, would you like to give a quick overview of Spyre, and then we can move to some Q&A?
Of course. Yeah. In general, our overall goal at Spyre is to create a set of products that raise the standard of care for serious autoimmune diseases. Our strategy is, I think, pretty straightforward, which is basically find what we believe are the best targets in the space, engineer antibodies that have optimized properties relative to what's out there today, and then combine them together in combination therapies in these markets. I think broadly in the disease spaces where we're playing, we've seen over the last few decades a lot of success in terms of new therapies that provide patients options, yet many of them hit what physicians call the therapeutic ceiling, where despite half dozen approved classes in IBD, for example, we don't do better than about a 25% placebo-adjusted remission rate.
For a disease that affects north of 2 million people in the U.S., I sincerely hope we can do better than that. I think we have increasing evidence over the last few years that combining multiple mechanisms is able to do that, which is not overly surprising given that these are heterogeneous diseases, so blocking multiple pathways has a good shot. We are working on that in inflammatory bowel disease and a dermatologic disease called HS, where we think these combinations can really elevate the standard of care.
In IBD, you have a Phase II PoC trial ongoing in UC called SKYLINE, which is evaluating your long-acting alpha-4/beta-7, IL-23, and TL1A as monotherapies as well as three combinations of those components. Can you remind us on a high level, what is the goal of this trial, what is the design, and what data have you shown so far from the Part A portion?
Yeah. We think this is a very innovative and efficient study in IBD that we were really uniquely positioned for because we had this portfolio of these three long-acting antibodies at the same time. To develop a combination therapy, you need to show what is called contribution of components. The monotherapies need to beat placebo, and then the combinations need to beat their components. We could have run this as three separate combination studies, combo, mono, and placebo, but by running it as one platform study, we can have one shared placebo, each of the monotherapies once, and then all of the three combinations.
This lets us run a study, still very large, north of 600 patients, but it lets us test what I think may be the three best combinations in development, maybe the three best products overall, and do it in an efficient way where they have all the right comparators in a single study. I think now that we have clarified the timing of the readout next year, where we will share all of this in one large readout in the third quarter, I think it actually highlights how efficient this study was, because we started enrolling the second part of this study in April. We expect to be done enrolling it in the first quarter of next year to provide that readout in the third quarter, which means we have enrolled north of, we will be in, have enrolled north of 600 patients in less than 12 months.
Remarkably fast, I think indicates the level of enthusiasm for this study and this approach overall. Again, you mentioned it's a two-part study, and Part A, that's what we've reported all the data for this year. This is just providing preliminary proof of concept that each of these monotherapies work as we expect. I think we showed that at least that good for our three monotherapies. I think our TL1A and our IL-23 performed like their class did, and then I think our alpha-4/beta-7, SPY001, might have even exceeded that and looked like the higher dosing and target coverage that we provide with our molecule might actually improve from the first-generation alpha4 antibody.
That really is showing each of these monotherapies work the way they expect, though it really only sets up what we think is really the exciting readout next year of seeing what happens when we put them together.
Is the maintenance data from Part A important, and when should we expect that?
Yeah. The study is a treat-through design study, meaning that, at week 12, we look at what's called the induction dataset. That's what we reported this year. Then for each of these arms, it continues till week 48, which is the maintenance dataset that you're referring to. So for each of these cohorts, about nine months after we have the induction data, we'll get the maintenance datasets. However, for Part A, I think the maintenance datasets, it's 40-odd patients per arm, three different maintenance datasets. We'll get the last one from our IL-23 kind of around the middle of the year, and I would expect kind of from that point or sometime thereafter at a medical conference, I expect we'll share all the maintenance datasets together for those three.
I would doubt there would be any major surprises in the maintenance data given what we know about each of these classes and how they perform from induction to maintenance.
Okay. As you mentioned, you recently confirmed the part B combination readout would be in the third quarter of 2027, and this will be one big readout. Can you help us understand what will be included in this update, including the scope and the level of detail that you plan to disclose?
Yeah. I think it should be one of the most interesting readouts in IBD that has occurred for quite some time and going forward as well, where we're testing each of these combinations and their components head-to-head against each other. I think it will be one of the more interesting datasets we've seen. We plan to report them all out at the same time. Again, that's the efficiency of the design, to be able to compare them against each other and really help us prioritize really in what order we're going to be advancing products to phase III thereafter. The key result, the primary endpoint is clinical remission. So that's really what the primary determinant is. Of course, we'll look at a whole host of other secondary and exploratory endpoints as well, and of course, safety is key too.
I expect it will be a very large readout, how we'll read out all of them all at once and not overwhelm folks. We'll have to figure out, but we'll have a ton of data to go through, and hopefully we'll have at least one, and I think it's reasonably likely we'll have more than one product that look like indication-leading products in this market.
What would you consider a successful outcome for each of the combinations?
Yeah. I think broadly, the course of the history of IBD, this is a very serious disease that has irreversible consequences. What that has led to is a treatment paradigm that the physicians call top-down therapy. What it basically means is we should use the most effective drugs first. We shouldn't step up and use less effective drugs and then build up to the better ones. What we've seen in this space is that when new products come out that are more effective than the last ones, they really take most of the market relatively quickly, even as those older products go biosimilar and are now at a lower price point. In terms of what that bar is, we have three good examples of it.
We've seen three head-to-head studies in this space, ENTYVIO beat HUMIRA by about 8 points on clinical remission. Then SKYRIZI and TREMFYA both beat STELARA in a range of different studies, but all around 10 percentage points on clinical remission. Even as STELARA and HUMIRA went biosimilar, we see the sales that ENTYVIO, SKYRIZI, and TREMFYA are doing, even though they're at a much different price point than these now biosimilar drugs are. I think what that leads us to is 10 is about the bar still. I think if these combinations beat those drugs, of which are monotherapies, I think they might be better versions of those.
If we can beat our monotherapies by 10 points or more, I think these products would be likely to beat today's standard of care by 10 points or more, and I think that would make them likely the indication-leading products commercially as well.
Is that on clinical remission? Yeah. Okay.
Yeah. I think, ideally, we want to see it across a range of endpoints. I think totality of data is what's going to be important. We want to see it wins on endoscopy, we want to see it win on remission. I think what we've learned about combinations is that they tend to win even more the deeper you look at an endpoint. So, on things like clinical response, they still win, but actually, statistically, they win more when you look at a harder endpoint like clinical remission. I think you can look even deeper at histologic and endoscopic improvements. I think we'll continue to see that that's where combinations differentiate. Again, if we look at the real-world evidence in IBD, there's a recent study called the VERDICT study that was presented just a few weeks ago at UEGW and other real-world publications.
The deeper we get patients into remission, the better they do in the long term. I think that will continue to move the market to these more effective therapies, which again, I think are likely to be the combinations.
You mentioned UEGW. I know AbbVie shared their full TARGET-CD data there. Obviously, Crohn's disease, not UC, but can you talk about these recent developments with other combos like AbbVie's and how that kind of impacts your current view of the probability of success of each of your combinations?
Yeah. I think this year, we've seen a lot of data that supports the idea that combinations tend to provide at least some level of additive efficacy, if not substantial additive efficacy. I would go back the J&J trials and the VEGA study and then the DUET trials, and then this most recent AbbVie study. That adds on top of decades of real-world evidence and animal studies and others suggesting that blocking multiple pathways is going to do better. Getting to this AbbVie result, I think they saw north of a 10-point improvement on endoscopic remission at week 12. That widens to 20 points by week 24. I think that result is well above the bar that I was talking about before in terms of that product should supplant the monotherapies with that level of improvement.
I think you see that in the enthusiasm among the community and among the large strategics like AbbVie that this is a winning product here that's going to take a large share of the market. I think a few things that were helpful there for us is that an alpha-4/IL-23, an alpha-4 combo in general is the thing that you might have been less enthusiastic about in Crohn's disease. I think as a monotherapy, ENTYVIO and alpha-4/beta-7 is perceived at least to be less effective in Crohn's. The fact that we see that level of additivity in Crohn's gives us a high level of confidence that taking an alpha-4/beta-7 combo into Crohn's, I would think you should have at least that level of confidence, if not more so, in ulcerative colitis, where alpha-4/beta-7 really is one of the best products in the space.
What about the IL-23/TL1A combo? Have we had any evidence of efficacy there yet?
TL1A is a much newer class, right. We don't have any approved TL1A agents yet, and so physicians don't have the opportunity to use TL1A agents and then add something else to it. The answer is not really have we seen TL1A combos in IBD per se. That said, we've seen TNF plus IL-23, and TNF and TL1A, they're not the same, certainly. I actually think we, I think, have good confidence that TL1A is superior to TNF. Not head-to-head superiority yet, but I think that's the case. TNF plus IL-23, we have seen additivity for. We saw that from the J&J trials, especially in the naive context in those early line patients, really a nice result. I suspect we're very likely to see that TL1A is likely to be a mechanism that combines with both alpha-4 and IL-23 as well.
Great. In terms of next steps, once you have the data in the third quarter, what will go into the decision around which combination or combinations to move forward?
Yeah. In general, I think advancing things to phase III in IBD is not for the faint of heart. These are large phase III studies to go after, and I think we have to believe that they're going to take meaningful market share in the ultimate commercial market to advance these. That said, I think there's a pretty high probability that these combinations are going to show that type of profile where we get at least 10+ points of additive efficacy between these. We've so far seen that combinations are well-tolerated from a safety perspective. That includes with TNF agents, which individually are less well-tolerated than our three. Then all of our combinations, we believe we can advance on a four-shot-a-year basis, which would be superior actually to any monotherapies on the market today.
If we see that profile in terms of additive efficacy, no safety downside, most convenient product in the space, I think these are the indication-leading products. I think they would be more than sufficient to justify the return on a phase III cost. I think the question would be how many of them we advance and which one goes first, which I think are going to be very interesting questions for us to puzzle out as we look at the data.
How sure are you that you can go directly into phase III?
Yeah, I think, the key question to answer, this study is looking at monotherapy, dose ranging, and contribution of components. These are kind of two of the key things that we need to answer, and we know the question that we haven't answered yet is combination dose ranging. Our expectation is, if successful in this study, we'll show kind of monotherapy dose and exposure response, and we'll hopefully show contribution of components for at least one of these combinations. I think that should let us go forward to phase III with a couple doses against a comparator, and I think that should be a reasonable path forward. I actually think we've seen in some cases, even if you don't quite hit that, the first phase III for combination started a few months ago from J&J.
They never quite hit contribution of components in phase II, and their phase III is still a reasonable-sized two-arm phase III study, nothing extraordinary, no factorial dose ranging or anything overly complicated and large. I think it reflects kind of a reasonable amount of regulatory alignment that we need an approachable path to get these things to market.
Okay. I want to talk a bit about competition. I think this comes up a bit with investors, especially given AbbVie and J&J are big players in IBD, and other people, including those two companies, are developing combinations. Maybe firstly on differentiation, how could Spyre's combinations differentiate from companies that are developing the same or similar combinations to those?
Yeah. I think we were a little bit the beneficiaries of being at the right place at the right time when the VEGA study came out. Until then, most players were working on whatever monotherapies programs they thought were interesting, but no one was taking kind of somebody else's drug and making that in addition to the agents that they had. When the VEGA study came out and everyone, I think, rationally looked forward and said, "I think combos are going to be a big part of this forward market," they then had to cobble together combinations basically and go get assets from different places to be able to put together into their combinations. That's not the situation that we were in.
We were making long-acting versions of the best biologic targets, and we could actually pick antibodies that could co-formulate with each other at very high concentrations, similar half-lives, and then develop them in a sufficient way. I think that difference in starting point leads to quite a big difference in the product profiles that we're looking at versus others in this space. As I mentioned, we have long-acting co-formulated products that we think in phase III we're going to be dosing four times a year in auto-injectors. That is a very strong product profile that I don't think anyone can match in this space. I think we see a mix of drugs that are dosed on different intervals that try to be combined together. You tend to default to the lowest common denominator in terms of whichever the worst dosing profile is.
That's the dosing profile for your combination. We see on-body devices instead of auto-injectors, clearly not preferred. We even see mixes of oral and injectable things getting combined together, which is a challenging product that really no one prefers from a convenience perspective. Some people prefer a pill a day. More people actually prefer four shots a year to one pill a day. No one wants to be doing both. I think this is a unique setup where we have the best versions in development of each of these combinations, and so I think whichever wins or whichever winners we advance forward, I don't believe there are alternatives out there that are actually superior. I think they're mostly inferior and mostly behind.
Okay. I wanted to ask about timelines then. Do you have a good idea of if you're in the lead on each of these combinations? Because I know AbbVie's IL-23, alpha-4 beta-7, they have presented data, but they're doing some more phase II-B work first, so.
Yeah. Well, clearly J&J's in the lead, right? They've started the DUET ENCORE study, phase III trial. I expect that's an approvable study, and obviously we're not there yet. I think AbbVie and our alpha-4 and IL-23s, I think it is a little bit uncertain right now in terms of the lead. I mean, our timeline, I think we're pretty clear on. We'll have the data in third quarter next year. We expect to be able to start phase IIIs in less than a year after we have those data. So, I think our timeline, we know. The AbbVie setup is a little bit different, and I think we'll see when they're able to start phase III. I think our phase II design is quite a bit more robust than the TARGET-CD study, which was open-label and no placebo comparator.
Ours is a blinded study with a placebo comparator, with multiple doses of our monotherapies. Those were not included in the AbbVie study, and I think it makes sense that they're now running the phase IIb study as well. If they wait for that, they're certainly not ahead of us. If they try to launch a phase III ahead, we'll see what that design looks like relative to ours. I think those are the ones that are reasonably close. On the other combinations, I don't think anyone's close. For the TL1A combinations, I think we're meaningfully ahead.
Okay. I think we might be expecting some other combination data from other competitors like Lilly maybe later this year. How are you thinking about that? I don't know if it's going to come ahead of your readout or your readout, so it's a bit difficult to-.
Yeah.
To judge?
Yeah, I think there's a number of other combos in development. Takeda's running a number of combination trials, as is Lilly, and we always see real-world evidence for combinations. I think in most cases we've seen these be supportive in terms of showing that combinations can add up. I don't believe there's a readout that's likely to come before ours with a product profile similar to ours that could be in phase III on a similar timeframe as ours.
Okay. A couple of commercial questions then. Firstly on pricing. What is your latest view of pricing of combinations? Do they need to be in line with the current standard of care biologics for payers to cover in first line, for example?
Yeah. It is obviously really early to be talking about pricing. That said, I think, we have seen, and I reference kind of these transitions in this field over the last 10, 15 years, that at branded price points, even as the inferior products go biosimilar, we have seen the market grow through them, and these new branded drugs at 10 points better retain kind of substantial growth and see that they take the lion's share of the market. I think that would not be the case if those were priced at double the price of a single biologic. I think our situation that I think is value maximizing for our shareholders, it is value maximizing for the patients as well, is to price our combinations in the range of the existing branded drugs.
I mean, if you are doubling their efficacy or beating them by a material amount, you can likely take some premium, but I don't think the right answer is going to be pricing it at double the price of the current branded drugs. I think if you are superior on efficacy, similar on safety, more convenient, and you price around the same place, that is how you get a dominant product that gets used really throughout the course of the disease, and I think that is how you take the lion's share of this market. That is really our base case.
That makes sense. Do you think that combinations could be used in earlier line and later line?
I think so, and I hope so. I mean, again, we have seen studies in IBD. I think the PROFILE study in Crohn's disease is the best example, where they tested a top-down therapy approach, best drug first, versus a step-up approach where we are going to save the better drugs for later. Definitively, the answer is use the better drugs first. Not just on long-term outcomes for the patients, but also cost-effectiveness.
That is, again, it comes back to this disease being a disease with irreversible consequences, fibrosis, stenosis, hospitalizations, resections. You do not get that back if you let somebody not continue flaring and not be in remission. I think what we will see is that if these drugs are priced rationally with better efficacy and good safety, good convenience, they are going to get used early and often. I think that is going to be the case here.
If all that falls into place, what percentage of the total IBD market do you think could ultimately move to combination therapy?
I think if you look over the last 10 to 15 years, the top handful of drugs, and I mean the top three drugs really, take 2/3 or more of the market. That was the case when it was HUMIRA and STELARA, and that is the case now when it is ENTYVIO, SKYRIZI, TREMFYA, Rinvoq. I mean, this is a highly concentrated market to the top drugs. Ultimately, I think there is going to be less of a comparison of combos versus monos or delta between the two. It is going to be, let us look at the product label and say, "What is the efficacy? What is the safety?
What is the convenience, and what is the price?" If these combos come out with a profile that I was talking about, I think they will be some of the top products in the space, and I think the top products in the space are going to continue taking the lion's share of the overall market. So, I think these combos will be well north of 50% in terms of the market that they take.
Okay. Maybe we can move on to your dermatology side. You have two long-acting TL1A programs, and you are looking at HS following some positive data from Merck in this indication. Could you walk us through both of these programs and when we should start to see data from each one?
Yeah. I think, as background here, HS is certainly not the level of mature market that IBD is in terms of understanding how the market shakes out. I would say that HS has a lot of the same features that IBD does in terms of it is a disease that also has serious irreversible consequences in terms of fibrosis, tunneling, loss of range of motion. You do not get those back if you lose them. I suspect we are going to see the same type of movement towards a top-down treatment paradigm in HS as we do in IBD. Again, that is why we are very excited about this combination as something that could, I think, or has a good probability of beating the individual monotherapies. That said, we are not there yet.
From that perspective, dermatologists tend to do step-up for many of their indications as well, starting with something safer. When the Merck data came out a few weeks ago, those results looked in line with kind of the best current standard of care in the space from an efficacy perspective. So far, we have seen across a large number of studies now, phase II and phase III, the TL1A seems to be better tolerated with fewer kind of adverse events than the current standard of care class. We see our TL1A is quite differentiated relative to Merck's as well. It is about three times the half-life, about 10-fold the potency.
We think that if you have the level of efficacy of the best thing in the space, you have the safer product, and we think we can dose ours much less frequently than the existing standard of care, I think that is potentially the best monotherapy. Then we are now combining the two best monotherapies in the space with, I think, a very reasonable chance that those are going to show some additivity, and that combination would be superior to either of them alone. In terms of how this is going to play out, we expect to be starting a pivotal study next year, sometime around the middle of the year, and then we expect to read out our combination proof of concept study towards the end of the year. We say, end of 2027, early 2028. We will see how quickly the study enrolls.
We've only been enrolling it for a couple months now, but it's two active arms. It's Bimzelx versus the combination of TL1A and Bimzelx. I think it makes sense that this should be a very attractive study to participate in, and I think we'll see rapid enrollment in the trial.
Okay. Can you talk a bit about the bar for success in the SKYLIGHT trial versus bimekizumab alone?
Yeah. We surveyed dermatologists in terms of asking them, what different profile would change your view and want to use the combination first? It's actually not that different from what we see in IBD, that the breakpoint is somewhere around 10 points of differentiation. Here, it's on one of the HiSCR scores, either HiSCR50 or HiSCR75. In this trial, we're using HiSCR75 as the primary endpoint, and that's actually learning from what we've seen in IBD, as I mentioned previously, that the deeper endpoints, you tend to see greater differentiation of the combos. I suspect on HiSCR75, maybe on even tougher endpoints is where we'll see that combo differentiate more. I think, again, if you beat it by 10 points and you don't see safety downsides, and you price it rationally, why would you not use that product?
Obviously, there's a lot of companies now going into HS. Wondering how you see the kind of landscape developing and what could end up being the most important therapies in this space?
It's much earlier innings. We're just trying a number of mechanisms in this space. I think even in the last weeks and months, we've seen some fall off in terms of not providing the same level of efficacy of the leading, the existing standard of care. Again, I suspect it will end up looking like IBD, where we may find a half dozen different classes work, maybe in the same range of efficacy, and it'll be a question of, can you beat that by combining them together? I think that's a good bet. We see the same type of evidence that led us and Merck and others to think TL1A should work on its own. They also suggest that these are mechanisms that are at least partially, if not mostly orthogonal, meaning you're blocking different paths of this disease.
We know it's a heterogeneous disease where not everybody responds to each individual mechanism. I suspect it's not the same person that would respond to TL1A and to IL-17, and maybe somebody will respond better when they're given both. So, this is all hypothetical for now, but I think it's a reasonable bet that we're going to see some level of additivity in an overall population of HS patients.
Okay. I'll pause here and see if there are any questions from the audience. Oh, yeah, we have one at the back.
Especially in HS, we've seen more incidence of the placebo arm surprising. Is that something that's an even more of a consideration for you, and how do you control for that?
Yeah, I think it's a very good question. The answer is yes, we have seen quite a bit of variability in placebo responses. I think there's a few things we can do. One of the key things is controlling for antibiotic use, both in terms of inclusion criteria and which antibiotics and how many patients are allowed to be on it, as well as stable antibiotics use going in, and then defining the endpoints in terms of which antibiotics specifically count as non-responders. I think what we've seen is using HS-specific antibiotics as defining non-responders versus general antibiotics is a better answer. I think that's, from a design perspective, I think that's key. The other point that I would suggest, especially as we move into combos, placebo rates tend to not be as high on the deeper endpoints.
You simply don't get to HiSCR75 or higher numbers for patients on placebo, more variability and larger numbers on the easier to hit endpoints. I think that lowers the likelihood that you see a major placebo effect. Lastly, this first study is not no placebo in this trial. It's Bimzelx versus the combination of TL1A and Bimzelx. I think we'll be able to look at our result for Bimzelx and compare it against their prior studies to see, okay, do we have a similar patient population and a similar result as they've seen in larger trials as well?
In the last couple of minutes, maybe we can just touch on the recent TL1A readout in PsA and axial, which was a negative update. What are you able to share about these latest results, and how should we think about the potential for the TL1A mechanism in rheum now?
Yeah. I think over the course of the year, I think there will be seven TL1A readouts across We showed three rheumatic diseases. Merck and Roche are looking at other indications as well. I think overall, it's a very promising mechanism across, but you have to run the clinical study to see just how good it is. Mice and genetics and the rest can only go so far. I think we ran three. I think our RA result was reasonably encouraging in terms of certainly an active drug at the primary and many of the secondary endpoints. In PsA and axial, we didn't hit the primary endpoint, and in our view, we have a lot of exciting places to spend our resources in IBD and HS. I think we have the best mechanisms and their combos.
In the rheumatic diseases, it doesn't appear to us that TL1A is one of those top 2, top 3 mechanisms in the space, and we don't think the right use of investors' money is to then go explore different combos in those indications if you don't have one of the leading mechanisms. I think it's really us. I think it's a very reasonable bet. I think we should prioritize the areas where we can have those dominant indication-leading products.
Okay. Well, I think that's all we've got time for. Thank you so much, Cameron. This has been great, and looking forward to 2027 for Spyre.
Us too. Thanks.